A Phase 2 interventional study of SHR6508 and SHR6508 in Secondary Hyperparathyroidism, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hyperparathyroidism, Secondary with a site in China — 4 open to participants now, 5 under way, 1 of them phase 3. Hyperparathyroidism, Secondary · China.
Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 2, and was the 13th registered.
188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.
Browse Hyperparathyroidism, Secondary studies →4 of the 23 studies in Hyperparathyroidism, Secondary with a site in China are open now. Recruiting first, the newest first:
Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18+
Shaanxi Micot Technology Limited Company · Sites in China
Ages 18+
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–70
Limeng Chen · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2023.
This study's enrollment of 75 is above the median of 62 across 146 interventional studies indexed under Hyperparathyroidism, Secondary.
Median enrollment 158 across the 18 interventional studies, 192 across the 5 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Hengrui Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 30 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 6 studies filed under Hyperparathyroidism, Secondary — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperparathyroidism, Secondary with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07122401Phase 3Shaanxi Micot Pharmaceutical Technology Co., Ltd.Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | 2026-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR6508
Drug: SHR6508
Drug: Cinacalcet
SHR6508
SHR6508
Cinacalcet
Change From Baseline in serum iPTH
iPTH was tested at a central laboratory.
Time frame: Baseline and the efficacy period, defined as Week 16
Proportion of Participants to End of Study whose iPTH decreased by≥30% from baseline
iPTH was tested at a central laboratory.
Time frame: Baseline and the efficacy period, defined as Week 16
Proportion of Participants to End of Study whose iPTH decreased to 300 pg/mL from baseline
iPTH was tested at a central laboratory.
Time frame: Baseline and the efficacy period, defined as Week 16
Change From Baseline in serum cCa and P
cCa and P were tested at a local laboratory.
Time frame: Baseline and the efficacy period, defined as Week 16
Participants With Treatment-Emergent Adverse Events (TEAEs)
Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA)
Time frame: Day1 to End of Study, End of Study is about Week 20
Participants with Anti-SHR6508 Antibody at baseline and postbaseline
Time frame: Day1 to End of Study, End of Study is about Week 20
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Oct 2023, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR6508
Hyperparathyroidism, Secondary →
Shanghai Hengrui Pharmaceutical Co., Ltd. →